01.12.2019, 2374 Zeichen

Marinomed: Marinomed Biotech AG, a globally active biopharmaceutical company with headquarters in Vienna, achieved several important milestones in the first three quarters of 2019. With the products of the Carragelose^® segment, the first causal therapy for colds and flu infections, Marinomed achieved a slight revenue growth of Euro 3.30 mn in the first nine months of 2019 (1-9/2018: Euro 3.23 mn). In order to achieve its long-term growth targets, Marinomed primarily focused on investments in research and development in the first three quarters 2019. These expenses stood at Euro 3.19 mn, significantly higher than in the prior-year period (1-9/2018: Euro 2.11 mn).  The result for the first three quarters 2019 stood at Euro -6.15 mn, after Euro -3.81 mn in the prior-year period. The company expects a continued positive order and sales performance in 2019.
Marinomed Biotech: weekly performance: -0.95%

Warimpex: Warimpex Finanz- und Beteiligungs AG delivered the strongest quarterly results in the company’s history. During the reporting period, the real estate development and investment company generated a profit of Euro 57.5 mn – in comparison, a loss of Euro 6.5 mn was reported for the third quarter of the prior year. These results were largely driven by gains on the disposal of properties, an accounting gain on the purchase of loans of former minority shareholders of a Russian group company, and exchange rate gains. Total revenues rose to Euro 23.3 mn during the first three quarters of 2019, while expenses directly attributable to revenues remained constant at Euro 9.2 mn. “The current financial year is shaping up to be one of the most successful years in the history of Warimpex. We will continue on our successful course, which is shaped by the focus on building up our property portfolio, creating new offerings, and strengthening our earnings potential. We have a number of exciting activities on the agenda, including development projects in the Polish cities of Krakow and Białystok, the refurbishment of the hotel in Darmstadt without disrupting ongoing operations, and the continuing development of AIRPORTCITY St. Petersburg in Russia. All of this makes us optimistic for the future,” said Warimpex CEO Franz Jurkowitsch.
Warimpex: weekly performance: 7.32%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (29/11/2019)

Christian Drastil: Wiener Börse Plausch

SportWoche Podcast #105: Lisa Reichkendler, mit ihrem Food Marketing und Peast Performance ev. zu einem Sportgeschichte-Riegel

Bildnachweis

Aktien auf dem Radar:Palfinger, Amag, SBO, Flughafen Wien, AT&S, Frequentis, EVN, EuroTeleSites AG, CA Immo, Erste Group, Mayr-Melnhof, S Immo, Uniqa, Bawag, Pierer Mobility, ams-Osram, Addiko Bank, Wiener Privatbank, SW Umwelttechnik, Oberbank AG Stamm, Kapsch TrafficCom, Agrana, Immofinanz, OMV, Österreichische Post, Strabag, Telekom Austria, VIG, Wienerberger, Warimpex, American Express.

---